Advanced search
Publication Cover
Postgraduate Medicine Volume 128, 2016 - Issue 4
Submit an article Journal homepage
449
Views
2
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes - Practice Pearl

Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes

Robert GuthrieEmergency Medicine, The Ohio State University, Dublin, OH, USACorrespondence[email protected]
Pages 335-337 | Received 09 Feb 2016, Accepted 01 Apr 2016, Published online: 18 Apr 2016

References

  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
  • The Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52–60.
  • The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;575(9733):2215–2222.
  • Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol. 2002;156:714–719.
  • UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
  • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998;352:854–865.
  • Evans JMM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. diabetologia. 2006;49:930–936.
  • ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–828.
  • ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
  • ACCORD Study Group Writing Committee. 9 year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016. Epub 2016 Jan 28. doi:10.2337/dc15-2283
  • Guthrie RM. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med. 2013;125(3):21–32.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.